Biopharmaceutical manufacturing markets for bioprocessing and bioreactors projected to grow

The global biopharmaceutical manufacturing sector is seeing significant growth in specialized production technologies, specifically in continuous bioprocessing and single-use bioreactors.

The continuous bioprocessing market, valued at USD 319.77 million in 2025, is projected to reach USD 2.33 billion by 2035, representing a compound annual growth rate of 21.98%. This growth is driven by the need for efficient, scalable production of monoclonal antibodies, vaccines, biosimilars, and cell and gene therapies. Key industry players include Thermo Fisher Scientific, Sartorius, Danaher, and Merck KGaA.

Simultaneously, the single-use bioreactors market is expanding as manufacturers adopt flexible, disposable systems to reduce cleaning requirements and cross-contamination risks. This market is expected to grow from an estimated USD 5.43 billion in 2026 to USD 9.58 billion by 2031. These technologies are increasingly utilized for producing recombinant proteins, viral vectors, and advanced biologics.